Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
AstraZeneca
Express Scripts
Moodys

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR CARVEDILOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Carvedilol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000294 ↗ Effects of Carvedilol on Cocaine Use in Humans - 11 Completed University of Minnesota Phase 2 1998-09-01 The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00000294 ↗ Effects of Carvedilol on Cocaine Use in Humans - 11 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1998-09-01 The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00000294 ↗ Effects of Carvedilol on Cocaine Use in Humans - 11 Completed National Institute on Drug Abuse (NIDA) Phase 2 1998-09-01 The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00004854 ↗ The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure Completed National Center for Research Resources (NCRR) Phase 1 1969-12-31 We would like to see if using Carvedilol in adjunct with Ace inhibitors will increase ejection fraction of the heart under echo. All interpretation of data will be sent to Boston Children's Hospital to be reviewed, which is the primary research center in this study. There are 5 hospitals participating in this study. The population targeted are children with moderate heart failure and must be on Ace inhibitors at the time of enrollment. Our outcome after placing them on Carvedilol is to change their ejection fraction on echo. The patients will be seen every 1-2 weeks, while we will titrate their medication to a maintenance dose. Secondary outcome is to increase quality of life, exercise tolerance and decrease their symptom scores as noted on their questionnaires.
NCT00052026 ↗ Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure Completed University of Utah Phase 3 2000-05-01 The purpose of this study is to determine whether a new medicine, called carvedilol, improves symptoms and heart function in children who have congestive heart failure (diminished function of their heart muscle that pumps blood to the body). To accomplish this, we will give carvedilol to some patients who have diminished heart function and congestive heart failure and see whether symptoms and heart function are better at the end of an 8 month period in those who received carvedilol compared to the other patients who did not receive carvedilol. We will be testing 2 different doses of carvedilol compared to no additional medicine.
NCT00052026 ↗ Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure Completed Shaddy, Robert, M.D. Phase 3 2000-05-01 The purpose of this study is to determine whether a new medicine, called carvedilol, improves symptoms and heart function in children who have congestive heart failure (diminished function of their heart muscle that pumps blood to the body). To accomplish this, we will give carvedilol to some patients who have diminished heart function and congestive heart failure and see whether symptoms and heart function are better at the end of an 8 month period in those who received carvedilol compared to the other patients who did not receive carvedilol. We will be testing 2 different doses of carvedilol compared to no additional medicine.
NCT00060918 ↗ Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension Completed GlaxoSmithKline Phase 4 2001-06-01 To evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in Type II diabetic patients with high blood pressure.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Carvedilol

Condition Name

Condition Name for Carvedilol
Intervention Trials
Hypertension 23
Heart Failure 22
Healthy 11
Cirrhosis 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Carvedilol
Intervention Trials
Hypertension 45
Heart Failure 42
Liver Cirrhosis 16
Hypertension, Portal 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Carvedilol

Trials by Country

Trials by Country for Carvedilol
Location Trials
United States 474
Japan 36
China 31
Canada 19
Korea, Republic of 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Carvedilol
Location Trials
New York 26
California 21
Texas 21
Florida 18
Illinois 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Carvedilol

Clinical Trial Phase

Clinical Trial Phase for Carvedilol
Clinical Trial Phase Trials
Phase 4 64
Phase 3 30
Phase 2/Phase 3 3
[disabled in preview] 74
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Carvedilol
Clinical Trial Phase Trials
Completed 96
Unknown status 30
Recruiting 19
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Carvedilol

Sponsor Name

Sponsor Name for Carvedilol
Sponsor Trials
GlaxoSmithKline 24
Institute of Liver and Biliary Sciences, India 10
National Institute on Drug Abuse (NIDA) 5
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Carvedilol
Sponsor Trials
Other 242
Industry 60
NIH 21
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Baxter
McKesson
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.